Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics

IP: Juan Ignacio Esteban Mur
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 135700
Reference: QLK2-2000-00836
Duration: 01/12/2000 - 01/12/2003

CIBER Enfermedades hepáticas y digestivas (CIBEREHD)

IP: Juan Ignacio Esteban Mur
Collaborators: Josep Quer Sivila
Funding agency: CIBER Enfermedades Hepáticas y Digestivas
Funding:
Reference: CB06/04/0028
Duration: 01/01/2007 - 31/12/2010

Selección y expansión de linfocitos CD4+NS3-específicos de pacientes VHC. caracterización del estado de anergia en cronicidad y restauración funcional para empleo en inmunoterapia adaptativa para prevención y tratamiento de la recurrencia postrasplante.

IP: Josep Quer Sivila
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Juan Ignacio Esteban Mur
Funding agency: Instituto de Salud Carlos III
Funding: 113740
Reference: PI061244
Duration: 01/01/2007 - 30/12/2009

Seleción y expansión de linfocitos T CD4+NS3-específicos de pacientes coinfectados por VIH y VHC. caracterización del estado de anergia en la infección crónica y restauración funcional para su empleo en inmunoterapia adaptativa para la prevención y/o tra

IP: Juan Ignacio Esteban Mur
Collaborators: Josep Quer Sivila
Funding agency: Fundación Innov. y Prosp. Salud en España - FIPSE
Funding: 85800
Reference: FIPSE/36623/06
Duration: 01/12/2006 - 30/11/2009

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Alba Torija Recasens

Alba Torija Recasens

Predoctoral researcher
Nephrology and kidney transplantation
Read more
Carmina Castellano Tejedor

Carmina Castellano Tejedor

Senior researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Concepció Jacobs Cachá

Concepció Jacobs Cachá

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Xavier Serra Ruiz

Xavier Serra Ruiz

Research technician
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.